Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$32.81M$32.81M+4.4% vs Q3 2023 Net Income-$4.85M-$4.85MN/M vs Q3 2023 EPS Diluted-$0.03-$0.03N/M vs Q3 2023 Gross Profit$23,352,000+76.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,371,000N/M Free Cash Flowderived$2,940,000N/M Margins · derivedGross margin71.2%+29.1 pt vs Q3 2023
Operating margin-13.6%+65.7 pt vs Q3 2023
Net margin-14.8%+64.8 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end